Second Look Lab — Research Brief: Selexipag for idiopathic pulmonary fibrosis (untested oral sibling of inhaled treprostinil)

Hypothesis-generating research brief from Second Look Lab, an independent drug-repurposing project. Selexipag, an oral prostacyclin (IP) receptor agonist approved for pulmonary arterial hypertension, has not been tested in people with idiopathic pulmonary fibrosis (IPF), although inhaled treprostinil, which also acts on the IP receptor, succeeded in the phase 3 TETON-2 trial (2026), and a 2026 mouse study reported that selexipag promotes alveolar regeneration and reduces bleomycin-induced fibrosis. The brief summarises the evidence, the main risks (systemic vasodilation, tolerability alongside nintedanib) and a proposed next step. It is a hypothesis only, not medical advice. Integrity: SHA-256 of the PDF = 8b53895a1a4759f2dc5e77f17903c3cd279df4c56c0f9bdb4032409809dc6c0e, timestamped with OpenTimestamps on 2026-11-11. Contact: [email protected]